MediciNova Announces Collaboration with the University of Sydney Concord Cancer Centre

Pharmaceutical Investing

MediciNova a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it plans to initiate a pilot study to evaluate MN-166 (ibudilast) in chemotherapy-induced peripheral neuropathy. As quoted in the press release: The clinical trial is a collaborative effort between MediciNova, …

MediciNova a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it plans to initiate a pilot study to evaluate MN-166 (ibudilast) in chemotherapy-induced peripheral neuropathy.

As quoted in the press release:

The clinical trial is a collaborative effort between MediciNova, Inc. and Dr. Janette Vardy, Professor of Cancer Medicine, University of Sydney Concord Cancer Centre in Australia. The proposed clinical trial will evaluate MN-166 (ibudilast) as a potential treatment for individuals with chemotherapy-induced peripheral neuropathy.  A Concord Cancer Centre Research grant will provide funding for this study and MediciNova will provide study drug.

Click here to read the full press release.

The Conversation (0)
MARKETS
COMMODITIES
CURRENCIES
Ă—